Florian Büttner1, Stefan Winter2, Steffen Rausch3, Anna Reustle2, Stephan Kruck3, Kerstin Junker4, Arnulf Stenzl3, Abbas Agaimy5, Arndt Hartmann5, Jens Bedke6, Matthias Schwab7, Elke Schaeffeler2. 1. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. 2. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany. 3. Department of Urology, University Hospital Tuebingen, Tuebingen, Germany. 4. Department of Urology and Pediatric Urology, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg/Saar, Germany. 5. Institute of Pathology, University Hospital Erlangen, Erlangen, Germany. 6. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Urology, University Hospital Tuebingen, Tuebingen, Germany. 7. Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Clinical Pharmacology, University Hospital Tuebingen, Tuebingen, Germany. Electronic address: matthias.schwab@ikp-stuttgart.de.
Abstract
UNLABELLED: There is evidence that molecular features support subclassification of tumours, thereby improving prediction of patient outcome. Currently, two gene expression signatures (ccA/ccB and ClearCode34) have been established to classify clear cell renal cell carcinoma (ccRCC). Because RCC arises from nephron cell types, we aimed to explore its heterogeneity on a molecular level by comparing gene expression between tumour tissue and nephron regions. Based on genes that differ in expression between nephron regions, expression data of 479 ccRCCs and 212 papillary and 66 chromophobe RCCs from The Cancer Genome Atlas were correlated to those of nephron cell types. Cancer-specific survival (CSS) of ccRCC patients was significantly associated with gene expression similarity to the proximal tubules. Subsequently, a ccRCC risk score (S3-score) was established. Survival analyses indicated that the S3-score was significantly associated with CSS considering all cases of ccRCC, as well as metastatic and nonmetastatic ccRCC. Results could be validated in an independent cohort. The S3-score significantly improved the predictive ability of the ccA/ccB and ClearCode34 signatures, and the clinicopathologic-based stage, size, grade, and necrosis score (p [chi-square] = 1.56E-04). Intratumour heterogeneity of the S3-score was observed in 6 of 10 ccRCCs. In summary, the nephron-based S3-score enables prognostic risk stratification for ccRCC. Further studies are needed to evaluate its clinical utility. PATIENT SUMMARY: We developed a novel risk score for clear cell renal cell carcinoma to identify patients at risk of worse outcome that may improve patient care in the future.
UNLABELLED: There is evidence that molecular features support subclassification of tumours, thereby improving prediction of patient outcome. Currently, two gene expression signatures (ccA/ccB and ClearCode34) have been established to classify clear cell renal cell carcinoma (ccRCC). Because RCC arises from nephron cell types, we aimed to explore its heterogeneity on a molecular level by comparing gene expression between tumour tissue and nephron regions. Based on genes that differ in expression between nephron regions, expression data of 479 ccRCCs and 212 papillary and 66 chromophobe RCCs from The Cancer Genome Atlas were correlated to those of nephron cell types. Cancer-specific survival (CSS) of ccRCC patients was significantly associated with gene expression similarity to the proximal tubules. Subsequently, a ccRCC risk score (S3-score) was established. Survival analyses indicated that the S3-score was significantly associated with CSS considering all cases of ccRCC, as well as metastatic and nonmetastatic ccRCC. Results could be validated in an independent cohort. The S3-score significantly improved the predictive ability of the ccA/ccB and ClearCode34 signatures, and the clinicopathologic-based stage, size, grade, and necrosis score (p [chi-square] = 1.56E-04). Intratumour heterogeneity of the S3-score was observed in 6 of 10 ccRCCs. In summary, the nephron-based S3-score enables prognostic risk stratification for ccRCC. Further studies are needed to evaluate its clinical utility. PATIENT SUMMARY: We developed a novel risk score for clear cell renal cell carcinoma to identify patients at risk of worse outcome that may improve patient care in the future.
Authors: Gabriel G Malouf; Xiaoping Su; Jianping Zhang; Chad J Creighton; Thai H Ho; Yue Lu; Noël J-M Raynal; Jose A Karam; Pheroze Tamboli; Frederick Allanick; Roger Mouawad; Jean-Philippe Spano; David Khayat; Christopher G Wood; Jaroslav Jelinek; Nizar M Tannir Journal: Clin Cancer Res Date: 2016-06-02 Impact factor: 12.531
Authors: Dennis Gürgen; Michael Becker; Mathias Dahlmann; Susanne Flechsig; Elke Schaeffeler; Florian A Büttner; Christian Schmees; Regina Bohnert; Jens Bedke; Matthias Schwab; Johann J Wendler; Martin Schostak; Burkhard Jandrig; Wolfgang Walther; Jens Hoffmann Journal: Front Oncol Date: 2022-06-21 Impact factor: 5.738
Authors: Wan Fangning; Ma Chunguang; Zhang Hailiang; Shi Guohai; Zhu Yao; Dai Bo; Shen Yijun; Zhu Yiping; Ye Dingwei Journal: J Cancer Date: 2017-07-05 Impact factor: 4.207